PM2C hosts second event in the MOHCCN Seminar Series
Researchers from the MOHCCN's Princess Margaret Cancer Centre Consortium (PM2C) presented during the second event of the Marathon of Hope Cancer Centres Network Seminar Series.
The event included presentations by Drs. Philippe Bedard, Lillian Siu and Alberto Hernando Calvo.
You can watch the entire presentation, below:
The event included presentations by Drs. Philippe Bedard, Lillian Siu and Alberto Hernando Calvo.
Related Team Members
-
Philippe
Project LeaderMOHCCN Network CouncilWorking Group Member
Bedard -
Lillian
MOHCCN Steering CommitteeInstitutional LeadConsortium LeaderWorking Group ChairWorking Group Member
Siu
-
Regional Consortia
Princess Margaret Cancer Consortium
- Ontario
The Princess Margaret Cancer Consortium coalesces the expertise and efforts of clinicians, pathologists, software developers and data and translational scientists to help accelerate precision medicine...Read more
Related News
-
Leadership and researchers at the Princess Margaret Cancer Consortium present updates to Network
The presentation was part of MOHCCN Seminar Series, which features virtual talks from MOHCCN research partner investigators and trainees, providing a platform for MOHCCN members to share their ongoing... -
Study Reveals Cause for Different Outcomes for Patients that Experience Early and Late Relapse of Diffuse Large B-cell Lymphoma
A recent study by MOHCCN-funded researchers at BC Cancer is helping to accelerate precision medicine for cancer by shedding new light on why some patients with relapsed DLBCL respond well to standard-... -
MOHCCN Pathfinder Project clears the way for future data sharing between Network members
Through its Pathfinder Project, the MOHCCN has developed and deployed a technical tool that allows members to upload, discover – and eventually access – the data needed to accelerate precision medicin... -
New study finds that location of immune cells is critical for immunotherapy response
An innovative new approach highlights the relevance of immune cells’ position within melanoma to inform on a patients’ response to immune therapy.